



# **The Potential Impact of TRIPS Plus IP enforcement Provisions on Access to Medicines in Africa**

Africa IP Forum 26 February 2013  
Midrand, South Africa

Tenu Avafia

UNDP, HIV, Health and Development Practice



# IP enforcement and the TRIPS Agreement



## Basic principles of IP Enforcement

- IPRs are private rights granted by the State
- The primary responsibility for IPR enforcement are the right holders, not the state
- IPR infringement: not easily determined for all IPRs
- Historically, countries had policy space to regulate IPR enforcement

## TRIPS Agreement

- Right holders seeking global “minimum standards” of IPR protection and enforcement
- Flexibilities exist in the enforcement of IP
- TRIPS+ rules further erode flexibilities and policy space for development





# TRIPS Agreement and impact on IP enforcement

- Key elements of IP enforcement in TRIPS Article 41:
  - There should be provisions in domestic law to take action against IP infringement
  - **Enforcement procedures must not create legitimate barriers to trade**
  - Procedures must be fair and not unnecessarily complicated or likely to lead to delays
  - Must be some form of review of first decisions made by administrative or judicial bodies
  - Members are not obliged to establish a separate judicial system to enforce IPRs
- **TRIPS Article 61** Criminal procedures and penalties are only required where there is **willful trademark counterfeiting** or **copyright piracy on a commercial scale**
- **TRIPS Article 46** The measure imposed should be **proportional** to the seriousness of the infringement



# Broader Enforcement Agenda



- Developed countries shifted focus to IP enforcement over past years
- US-EU 2006 Trans-Atlantic Agreement prioritizing IP enforcement
- 2006 G8 summit in Russia IP strategy statement: “Combating International Property Rights Piracy and Counterfeiting” strategies include:
  - keeping spotlight on trade in counterfeit goods
  - building capacity in developing countries to enforce IP
- Development of guidelines on border measures by G8 in 2007
- G8 Communiqué issued in 2008 encouraging acceleration of negotiations to establish ACTA
- December 2010, MEDICRIME convention adopted by CoE, 19 countries signed including Guinea and Morocco, Ukraine ratified



# The Broader Enforcement Agenda

(Source: Viviana Munoz Tellez, South Centre)





# Seizure of goods in transit

- EC adopted Regulation 1383/2003 allowing border measures on pharmaceuticals
- In 2008, Regulation was used to seize generic medicines in transit at various EU ports in France, UK, Holland, Germany
- Led to seizure/detention of medicines including AZT and Abacavir from India & China headed to e.g. Nigeria, Ecuador on at least 19 occasions
- Article 51 of TRIPS requires Member States suspend importation of counterfeit trademark or pirated copyright goods
- Critics argued that EC regulations and border measures violate inter alia, TRIPS Article 41, Article V of GATT, Doha Declaration
- WT/DS408 - European Union and a Member State - Seizure of Generic Drugs in Transit
- Resolved after consultations between India, Brazil, EU 7-8 July; 13-14 September 2010





# Impact of IP Enforcement on Medicine access

- Substandard medicines pose a real threat to patients
- Attempts to address problem by adopting IP enforcement measures can result in:
  - The Conflation of IP concerns with medicine quality which is traditionally dealt with by Drug Regulatory Authorities;
  - Delegation of IP enforcement to authorities with no adequate competency to determine IP infringement **or** medicines' quality and efficacy;
  - Divert substantial public resources which should be used to ensure quality, safety & efficacy to defend private rights;
  - Unwarranted delay of legally produced medicines



# Proliferation of Anti-Counterfeiting Legislation in the EAC and Beyond



- EAC comprises of 5 countries , 4 of which are LDCs,
- Initiatives to use TRIPS Flexibilities could be endangered by proliferation of “anti-counterfeiting” legislation, which could prevent use of TRIPS flexibilities:
  - Tanzania, Subsidiary Merchandise Marks Act, 2008;
  - Kenya , Anti-Counterfeiting Act ,2008;
  - Uganda, discussing a Counterfeit Goods Bill since 2008, Tabled in Parliament in early 2011
- Draft EAC Anti-counterfeit Policy and Bill are being discussed
- Several stakeholders have expressed concerns about public health impact of legislation





# Kenya's Anti-counterfeit Act of 2008

- Anti-counterfeit Act adopted in 2008
- Broad definition of counterfeit conflates quality and IPR issues; legitimate generics fall under definition of “counterfeits”
- Up to 90% of medicines in Kenya are generics (Source: HAI-Africa).
- Act was challenged before the High Court in July 2009 by three petitioners living with HIV
- Court passed preliminary judgment in favor of petitioners on 23 April, 2010
- Final judgment in 2012 found Act to be unconstitutional. Legislation Pending revision





# Uganda's Counterfeit Goods Bill

- Up to 93% are generics (Sources: IPS, HEPS-Uganda).
- Counterfeit Goods Bill – discussed since 2008. Initial definition of “counterfeit” very similar to Kenya’s law, TRIPS-plus. Included patents
- HAI/TWN/UNDP/OSI: co-sponsored an expert discussion on the Bill (Entebbe, September 2009).
- Bill examined from public health perspective: TRIPS-plus definition of “counterfeit”, contradiction with other laws, border measures, criminal sanctions
- Workshop with Parliamentarians, government & civil society 2012
- Reports are that a revised Bill was tabled before Parliament



# UNDP Discussion paper: Anti-counterfeit laws and public health: what to look out for



# Key elements of anti-counterfeiting legislation



- Meeting held by EAC/GIZ/UNDP on EAC anti-counterfeiting Bill and policy, December 2010

## 1. Definition Problems – what constitutes a “counterfeit”?

- TRIPS only uses the term counterfeiting to refer to trademark and copyright
- Overly broad definition can have serious implications for generic medicines: see 2012 ruling by Kenyan High Court
- Patents should not be included in anti-counterfeiting legislation

## 2. Criminal liability

- IPRs are private rights, should be enforced by right holder
- Criminalization requires the use of government resources to enforce private right
- Article 61 of TRIPS criminalizes only **willful** trademark or copyright piracy on a **commercial scale**
- Article 41 of TRIPS : provide safeguards to prevent the abuse of IP enforcement



# Key elements of anti-counterfeiting legislation



## 3. Powers of Seizure and Storage

- Laws giving broad powers to government to intercept and inspect any place, seize and detail goods, seal off any place (in Kenya w/o warrant) can easily be abused
- Legislative provisions should be in conformity with constitutional and human rights principles
- Judicial oversight important

## 4. Goods in Transit

- Some legislation criminalizes the transit/trans-shipment of counterfeit goods
- Anti-counterfeiting legislation should not pose a barrier to legitimate international trade, should comply with GATT obligations on freedom of transit





# Key elements of anti-counterfeiting legislation

## 5. Rules of Evidence

- Should prevent abuse of enforcement right by state or right holder
- Complainants should first establish their rights before alleging violation

## 6. Liability for loss or damage to goods

- Any person who suffers loss due to wrongful seizure, removal or detention should be compensated
- Should be a mechanism to hold responsible any person who allows loss or damage of legitimate goods





# Determining a Constructive Agenda

- Develop adequate measures to show no tolerance for substandard medicines, brand or generic
- Questions around whether IPR enforcement is best modality:
  - IPRs are private rights
  - Not suitable to ensure safety and efficacy of medicines.
- National drug regulatory authorities should implement safety and efficacy measures for medicines
- Countries should create legal and policy environment that enables implementation of health MDGs, including Goals 4, 5, and 6 by using TRIPS flexibilities as per UNAIDS/UNDP/WHO policy Brief on TRIPS and access to ARVs

